Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2011. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons under the GlaxoSmithKline Performance Share Plan.
Key Financial Metrics
The filing does not provide consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to specific share plan transactions:
- Share Price: Ordinary shares at £12.22 per share.
- ADR Price: $39.96 per ADR.
- Transaction Type: Increase in notional interests following the re-investment of dividends paid on April 7, 2011.
Material Changes
The filing does not report material changes to the company's financial position or operations compared to prior periods. It solely documents the administrative update of notional share holdings for plan participants.
Guidance, Outlook, and Risks
The document contains no management commentary, forward-looking guidance, risk factors, or contingencies. It notes that notional dividends accrued will be paid out in proportion to the percentage of participants' Performance Share Plan holdings that vest following the end of the relevant three-year measurement period.
Key Facts for Investor Verification
- Verify the vesting schedule and conditions for the GlaxoSmithKline Performance Share Plan to understand future payout obligations.
- Confirm the specific number of Ordinary shares and ADRs held notionally by each listed director and executive.
- Note that this filing is a regulatory disclosure of insider transactions and does not reflect the company's overall financial performance for the period.